Current heads of CBER, CDER snag permanent jobsnews2026-09-08T21:07:50+00:00September 8th, 2026|Endpoints News|
Pharvaris’ stock jumps on pivotal success in rare genetic diseasenews2026-09-08T18:29:02+00:00September 8th, 2026|Endpoints News|
Amgen’s T cell engager notches new major lung cancer victorynews2026-09-08T17:53:52+00:00September 8th, 2026|Endpoints News|
Sanofi spells out asthma data, AstraZeneca details COPD win at #ERS26news2026-09-08T16:24:59+00:00September 8th, 2026|Endpoints News|
Sandoz unveils plan for biosimilar expansion and new $300M factory in Slovenia news2026-09-08T14:14:32+00:00September 8th, 2026|Endpoints News|
Inhibrx targets OX40 agonist-cancer vaccine studies from early next yearnews2026-09-08T11:30:32+00:00September 8th, 2026|Endpoints News|
Updated: Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drugnews2026-09-08T08:24:44+00:00September 8th, 2026|Endpoints News|
FDA approves AstraZeneca’s oral SERD for breast cancer despite negative adcomm votenews2026-09-07T17:17:43+00:00September 7th, 2026|Endpoints News|
Novartis’ Phase 3 pelacarsen study miss raises the stakes for Amgen, Lillynews2026-09-07T14:48:28+00:00September 7th, 2026|Endpoints News|
The race to make new Ebola vaccines faces a cash crunchnews2026-09-04T15:34:26+00:00September 4th, 2026|Endpoints News|
